Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Diabetes (Germany)

August 13, 2008
Life-extending effect of Byetta ?
By a GLG Expert Contributor
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise (www.nytimes.com)
In a small subgroup of type-2-diabetes patients  in the ACCORD trial which had been treated with Byetta (825 of 10 000) a lowerde death rate was found as compared to the whole group.  This is a hypothesis-generating finding. Fewer hypoglycemias, even mild ones, may be an exüplanation for this...
July 29, 2008
A new gliptin - what is the difference to sita- and vildagliptin?
By a GLG Expert Contributor
Analysis of: AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes (www.astrazeneca.com)
As the member of an Advisory board for a gliptin ande not familiar with details on saxagliptin it would be interested to know what makes the difference to the gliptins already on the US and EU market. How is the DPP-4-specifity? Only for DDP-4 or also somewhat for DPP-9? Or other DPP´s ? What´s on with...

Page : 11 to 2 of 2

Analytics


Generated at 2009-01-07T19:00:58.307